都说治病要"对症下药"，可很多抗癌药在体内却像"天女散花"。一针药水打进血管，药物随着血液跑遍 全身，但真正能到达肿瘤病灶、发挥作用的剂量，少得可怜。更棘手的是，超过90%的晚期实体瘤患 者，会对经典的PD1/PDL1免疫疗法产生耐药，陷入"无药可医"的绝境。 西湖大学未来产业研究中心高晓飞课题组，从人体最普通的一管血里，找到了破局之匙。他们联合浙江 省人民医院和浙江大学课题组，让红细胞化身为精准的抗癌"快递员"，研发出全球首个红细胞—抗体偶 联药物，名为αPD1-Ery。在对传统免疫治疗耐药的晚期实体瘤患者身上，这款新药不仅安全性良好， 甚至让有的患者肿瘤完全缓解，为克服免疫治疗耐药提供了新的研究思路与治疗路径。这项研究成果于 2月20日发表于国际学术期刊《自然·癌症》。 这究竟是如何做到的？故事得从那个让人头疼的"耐药"说起。 高晓飞介绍，PD1/PDL1抑制剂曾是抗癌明星，它的原理是解除肿瘤的伪装，让免疫细胞重新攻击肿 瘤。可为啥用着用着就没效了？问题往往不是药物失效，而是战场上的"士兵"——能"打仗"的T细胞， 已经消耗殆尽了。 那怎么办？得从外面调"新兵"来。 脾脏，人体最大的外周免疫器官，全身三分 ...

Core Viewpoint - The Hong Kong stock market experienced a significant decline on the first trading day after the holiday, with major indices dropping sharply, indicating a bearish sentiment in the market [1][2]. Market Performance - The Hang Seng Index closed at 26,413.35, down 292.59 points or 1.10% [2]. - The Hang Seng Technology Index fell by 2.91% to 5,211.50 points, marking a new low in five months [4]. - The Hang Seng China Enterprises Index decreased by 1.22% to 8,959.56 points [2]. Sector Analysis - Technology stocks faced substantial losses, with major players like JD Health and Baidu dropping over 6%, while Tencent Music and Bilibili fell more than 5% [4][5]. - In contrast, AI applications and certain leading biotech companies saw gains, with some AI stocks like Zhiyuan and MiniMax experiencing significant increases in market capitalization [6]. Cryptocurrency Sector - Cryptocurrency-related stocks surged, with Star Chain Group rising over 122% [8]. - The Hong Kong Monetary Authority is evaluating applications for stablecoin issuer licenses, aiming to issue the first licenses by March [8]. Government Outlook - The Financial Secretary of Hong Kong expressed optimism about the market for the Year of the Horse, noting that historically, three out of four Horse years have seen double-digit percentage increases [9].

Core Viewpoint - The article highlights the operational resilience and community integration of Yunda Express during the Chinese New Year, showcasing the transformation of Liuyang Economic Development Zone into a vibrant urban area that supports both industry and community life [6][9]. Group 1: Operational Performance - Yunda Express's logistics center in Liuyang operates continuously during the Chinese New Year, with over 100 trucks daily and a workforce of 185 in the receiving department and 77 in the dispatch department [3]. - The average daily processing volume reaches 3.2 million packages during non-holiday periods, maintaining a stable volume of 350,000 packages even during the holiday [3]. Group 2: Community and Urban Development - The transformation of Liuyang Economic Development Zone reflects a shift from a traditional industrial park to a livable and workable urban area, integrating residential and commercial spaces [6][9]. - The presence of diverse communities is evident, with individuals from various regions choosing to celebrate the New Year in Liuyang, indicating a sense of belonging and community [7][8]. Group 3: Personal Stories and Community Integration - Personal narratives illustrate the deep connections individuals have formed with the new urban environment, as seen in the experiences of residents who have settled in Liuyang and contributed to the local economy [8]. - The article emphasizes the role of local initiatives in fostering community ties, such as the introduction of public rental housing and local businesses that cater to the needs of workers and their families [8].

Core Insights - The company expresses optimism about China's economic resilience and strategic direction despite external challenges and domestic transformation pressures [1] - The investment strategy focuses on sectors such as advanced manufacturing, artificial intelligence, biomedicine, new energy, and new materials, aiming for deep engagement and value creation [1] - The company has achieved significant milestones, managing nearly 30 billion RMB and investing in over 350 companies, with more than 40 successfully exiting through IPOs [1] Group 1: Market Environment - The macroeconomic narrative is complex, but three constants guide the company's judgment: the direction of technological revolutions, the urgent need for industrial upgrades in China, and the survival of the fittest in the venture capital ecosystem [2] - The technological revolution is characterized by advancements in AI, life sciences, energy technology, and low-altitude economy, which are accelerating towards industrialization [2] - The shift from supply chain security to excellence and from cost advantages to technological advantages is essential for survival and competition, creating historic demand for startups addressing core industrial bottlenecks [2] Group 2: Investment Outlook - The investment landscape is focused on four areas of certainty: the positive outlook for capital markets, the clarity of the industrial revolution led by AI and new energy, the commitment to technological independence, and the growing importance of health and wellness sectors [3][4] - China's stable economic growth positions it as a cornerstone of global economic development, enhancing the prospects for its capital markets [3] - The emphasis on domestic innovation in sectors like semiconductors, high-end equipment, and biotechnology is now a national strategy, creating a golden opportunity for companies with core technological capabilities [3] Group 3: Health Sector Investment - The changing population structure and rising health awareness are driving investment logic in the pharmaceutical and healthcare sectors beyond cyclical fluctuations [4] - Areas such as innovative drugs, high-end medical devices, and broader health management are seen as long-term investment tracks that combine technological attributes with social value [4] Group 4: Future Commitment - The company reaffirms its commitment to investing in early-stage, small-scale, and hard technology ventures, leveraging its deep research and industry ecosystem resources to identify resilient investment targets [5] - The outlook for the future is hopeful, with a call for collaboration to navigate the opportunities presented in the coming year [5]

Group 1: Robotics Sector - The Hong Kong stock market experienced a structural rally on February 20, with robotics stocks seeing significant gains following a notable performance at the 2026 Spring Festival Gala [1][9] - Key robotics stocks included: - Yujian (越疆) up 19.2% to HKD 47.56 per share - Suton (速腾聚创) up 9.42% to HKD 37.64 per share - Hesai (禾赛-W) up 6.64% to HKD 215.2 per share - UBTECH (优必选) up 6.74% to HKD 147.3 per share [1][9] - Suton announced a significant reduction in net losses for 2025 and reported a net profit of at least RMB 60 million for Q4 2025, marking its first quarterly profit [1][10] - Dongwu Securities highlighted advancements in core robotics capabilities as crucial for the sector's transition from laboratory to factory settings, projecting a new phase of growth from 2021 to 2025 [11] Group 2: Port Transportation Sector - The Hong Kong port transportation index rose by 2.11% on February 20, reflecting strong performance in the sector [2][12] - Notable stocks included: - COSCO Shipping Energy (中远海能) up 6.16% to HKD 8.26 per share - Seaspan (海丰国际) up 4.83% to HKD 1.7 per share [2][12] - Guotai Junan Securities reported that geopolitical tensions and high shipping rates are expected to lead to significant year-on-year earnings growth in Q1 2026, with oil shipping rates remaining elevated since September 2025 [12] Group 3: Biopharmaceutical Sector - The biopharmaceutical company, Basestone Pharmaceuticals (基石药业-B), saw its stock rise by 5.41% to HKD 6.23 per share, with a trading volume of HKD 48.43 million on February 20 [4][13] - Basestone announced that its CS2009 drug for late-stage solid tumors received IND approval from the FDA, marking a significant milestone in its global development [6][15] - The CEO of Basestone emphasized the importance of communication with the FDA and the positive results from the I phase clinical trials, confirming the II phase research plan [15]

Core Insights - The unexpected GDP ranking of provinces in China for 2025 has sparked significant online discussion, particularly regarding the surprising positions of major cities like Shanghai and Beijing, which did not make it into the top ten despite their strong economic performance [1][3][5]. Group 1: Economic Performance - Shanghai's GDP reached 5.67 trillion yuan, placing it ninth nationally, while Beijing surpassed 5.2 trillion yuan but failed to enter the top ten [5][9]. - The leading province, Guangdong, reported a GDP of 14.58 trillion yuan, significantly outpacing other provinces and cities, showcasing a clear economic gap [22][37]. Group 2: Comparative Analysis - The ranking highlights a stark contrast between the economic capabilities of Guangdong and the two major cities, with Guangdong's GDP being equivalent to 2.5 times that of Shanghai and 2.7 times that of Beijing [22][39]. - The population and land area differences play a crucial role in GDP comparisons, as Guangdong has a much larger population base of 128 million compared to the combined population of Shanghai and Beijing, which is under 50 million [27][39]. Group 3: Development Strategies - Shanghai and Beijing have shifted their focus from total GDP to high-quality development, emphasizing advanced industries such as integrated circuits and artificial intelligence, rather than competing solely on total output [19][31]. - Guangdong's economic strength is attributed to a balanced development across various sectors, including manufacturing, foreign trade, and emerging industries, which has allowed it to maintain its leading position for 37 consecutive years [37][49]. Group 4: Emerging Trends - The 2025 GDP rankings also revealed notable performances from provinces like Tibet and Gansu, which achieved significant growth rates, indicating a diversification of economic development across China [51][52]. - The overall GDP of China reached approximately 140.19 trillion yuan in 2025, reflecting a growth of 3.99% from the previous year, with Guangdong, Jiangsu, and Shandong entering the "ten trillion club" [46].

Core Insights - HHLR Advisors, a fund management platform under Hillhouse Capital, reported a significant reduction in its U.S. stock holdings, with a total market value of $3.104 billion as of the end of Q4 2025, reflecting a 24% decrease quarter-over-quarter [1]. Group 1: Portfolio Composition - HHLR Advisors held a total of 33 stocks at the end of Q4 2025, with a notable structural shift in its portfolio [1]. - Chinese concept stocks remain the core asset allocation for HHLR Advisors, with seven out of the top ten holdings being Chinese companies, accounting for 92% of the total market value [2]. Group 2: Key Holdings - Pinduoduo is the largest holding for HHLR Advisors, with shares increasing from 8.59 million to 10.72 million, and the market value rising from $1.136 billion to $1.216 billion, representing 39% of the investment portfolio [3]. - Alibaba is the second-largest holding, with shares increasing from 3.289 million to 5.43 million, and the market value rising from $588 million to $796 million, now making up 26% of the portfolio [3]. - Together, Pinduoduo and Alibaba account for 65% of HHLR's investment portfolio, solidifying their status as the "dual core" of the holdings [3]. Group 3: Recent Adjustments - In Q4, HHLR Advisors increased its holdings in TSMC while reducing its positions in Futu and Webull, and completely exited positions in Baidu and NetEase [3].

Core Viewpoint - Ferroptosis is a newly discovered iron-dependent form of programmed cell death that plays a significant role in the development of various diseases, including cancer, and is emerging as a promising new strategy for cancer treatment [2][4]. Group 1: Research Findings - The study published by the teams from Columbia University and the University of Pittsburgh reveals a non-canonical ferroptosis pathway mediated by the GPX1-OSBPL8 axis, which does not require external inducers like erastin or RSL-3 [3][4]. - This non-canonical pathway is part of the natural tumor suppression mechanism mediated by p53, driven by phosphatidic acid (PA) peroxidation induced by reactive oxygen species (ROS) [4][8]. Group 2: Mechanism of Action - The mechanism involves the recruitment of GPX1 to the endoplasmic reticulum (ER) by OSBPL8, where GPX1 reduces oxidized PA to prevent ferroptosis [9][10]. - The study identifies the endoplasmic reticulum as a key site for the initiation of non-canonical ferroptosis, contrasting with classical ferroptosis that primarily focuses on the plasma membrane [10]. Group 3: Implications for Cancer Treatment - The findings suggest that targeting the GPX1-OSBPL8 signaling axis with small molecule inhibitors could selectively induce ferroptosis in tumors, representing a promising cancer therapy strategy [15][16]. - The research enhances understanding of how p53 suppresses tumors through mechanisms like ferroptosis, providing new insights into natural anti-tumor immunity [17]. - The expression levels of OSBPL8 and GPX1 may serve as biomarkers to predict cancer sensitivity to ferroptosis-inducing therapies [17].

Core Viewpoint - The company, 英矽智能 (03696), has been selected by the Hang Seng Index Company to be included in the Hang Seng Composite Index, effective from March 9, 2026. This inclusion is expected to enhance the company's stock liquidity and broaden its investor base through a diversified shareholder structure, reflecting strong recognition of its industry position and business performance in the international capital market [1][4]. Group 1 - The company will be included in the Hang Seng Composite Index starting March 9, 2026 [1][4]. - The inclusion is anticipated to meet the eligibility criteria for trading under the Stock Connect programs (Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect) [1][4]. - The board believes this recognition will promote the company's long-term development and enhance stock liquidity [1][4].

Core Viewpoint - The collaboration between Harbin and Shenzhen is fostering innovation and new production capabilities, exemplified by the establishment of the Harbin New Area Shenzhen (Harbin) Industrial Park, which serves as a model for cross-regional scientific and technological cooperation [1][2]. Group 1: Industrial Development - The Harbin New Area Shenzhen Industrial Park has become a hub for various industries, including smart agriculture, equipment manufacturing, and biomedicine, showcasing the potential for cross-regional innovation [1][2]. - The park has registered 717 companies with a total registered capital of 24.2 billion yuan, and the first phase of projects has achieved over 90% occupancy, generating cumulative revenue exceeding 17 billion yuan [3]. Group 2: Technological Integration - The park integrates research capabilities from Harbin with market opportunities in Shenzhen, facilitating the transformation of technological innovations into practical applications [3][4]. - Companies like Huida Technology have successfully developed agricultural drones by combining Shenzhen's advanced technologies with Harbin's agricultural practices, significantly enhancing operational efficiency [2][3]. Group 3: Investment and Support - The collaboration has attracted investments from Shenzhen, including support from major enterprises like China National Offshore Oil Corporation, enhancing the local business environment [6]. - The park has implemented a "Friday Meeting" platform to facilitate communication between government, enterprises, and universities, promoting resource sharing and innovation [8]. Group 4: Talent and Infrastructure - The park offers 1,355 talent apartments with rental discounts to attract skilled professionals, ensuring a conducive environment for innovation [8]. - The total planned area for the Harbin New Area Shenzhen Industrial Park is 26 square kilometers, with ongoing projects aimed at creating a comprehensive industrial ecosystem [9].